Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia

Journal of Nephrology

Volumn 16, Issue 5, 2003, Pages 703-709

  Deira, Javier ^a   Diego, Julia ^a   Martínez, Rosa ^a   Oyarbide, Amaya ^b   González, Anunciaón ^a   Díaz, Hugo ^a   Grande, Jesús ^a  

^a HOSPITAL VIRGEN DE LA CONCHA   (Spain)

^b Seter Dialysis Center   (Spain)

Author keywords

Ascorbic acid; Desferroxamine; Hemodialysis; Hyperferritinemia; Iron overload

Indexed keywords

AMINOTRANSFERASE; ASCORBIC ACID; CARNITINE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FERRIC GLUCONATE; FERRITIN; FOLIC ACID; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; VITAMIN B GROUP; FERRIC ION; IRON CHELATING AGENT;

ADULT; AGED; ANEMIA; ARTICLE; BIOSYNTHESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESISTANCE; DRUG RESPONSE; DRUG USE; DRUG WITHDRAWAL; ERYTHROPOIESIS; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; HYPERFERRITINEMIA; IRON BLOOD LEVEL; IRON KINETICS; IRON OVERLOAD; IRON STORAGE; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; BLOOD; COMPARATIVE STUDY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

AGED; ASCORBIC ACID; DEFEROXAMINE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FERRIC COMPOUNDS; FERRITINS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 1442331922     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Richardson D. Clinical factors influencing sensitivity and response to epoetin. Nephrol Dial Transplant 2002; 17 (suppl 1): S53-9.
2. Cavil I. Iron status as measured by serum ferritin: the marker and its limitations. Am J Kidney Dis 1999; 34 (suppl 2): S12-7.
3. Kalantar-Zadeh K, Luft FC, Humphreys MH. Moderately high serum ferritin concentration is not a sign of iron overload in dialysis patients. Kidney Int 1999; 56: 758-9.
4. NKF-DOQI Work Group. NKF-DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001; 38 (suppl 2): S182-238.
5. European Survey Anaemia Management (ESAM). European Best Practice Guidelines 6-8: Assessing and optimizing iron stores. Nephrol Dial Transplant 2000; 15 (suppl 4): S20-32.
6. Macdougall IC, Chandler G, Elston O, Harchowal J. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Am J Kidney Dis 1999; 34 (suppl 2): S40-6.
7. Fishbane S, Maesaka JK. Iron management in end-stage renal disease. Am J Kidney Dis 1997; 29: 319-33.
8. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandau JV, Gupta A. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11: 530-8.
9. Kirschbaum B. Serial ferritin concentrations in hemodialysis patients receiving intravenous iron. Clin Nephrol 2002; 57: 452-6.
10. Feldman HI, Santana J, Guo W, Furst H, Franklin E, Joffe M, Marcus S, Faich G. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002; 13: 734-44.
11. Kletzmayr J, Sunder-Plassmann G, Hörl WH. High dose intravenous iron: a note of caution. Nephrol Dial Transplant 2002; 17: 962-5.
12. Patruta SI, Hörl WH. Iron and infection. Kidney Int 1999; 55 (suppl 69): S125-30.
13. Hoen B, Dauphin P, Kessler A. Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol 2002; 57: 457-61.
14. Kletzmayr J, Hörl WH. Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant 2002; 17 (suppl 2): S25-9.
15. El-ResHaid K, Jony KV, Hakim A, Kamel H, Sebeta A, Hourani H, Kanyike FB. Erythropoietin treatment in haemodialysis patients with iron overload. Acta Haematol 1994; 91: 130-5.
16. Hakim RM, Stivelman JC, Schulman G, Fosburg M, Wolfe L, Imber MJ, Lazarus JM. Iron overload and mobilization in long-term hemodialysis patients. Am J Kidney Dis 1987; 10: 293-9.
17. Lee Ch-T, Liao Sh-Ch, Hsu K-T, Lam KK, Chen J-B. Low dose desferoxamine can improve erythropoiesis in iron-overload hemodialysis patients without side effects. Ren Fail 1999; 21: 665-73.
18. Gasteldelao K, Vereerstraeten A, Zame-Nze T, Vanherweghem JL, Tielemans C. Resistance to erythropoietin in iron-overload haemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant 1995; 10 (suppl 6): S44-7.
19. Tarng D-Ch, Huang T-P, Wei Y-H. Erythropoietin and iron: the role of ascorbic acid. Nephrol Dial Transplant 2001; 16 (suppl 5): S35-9.
20. Giancaspro V, Nuzziello M, Payota G, Sacchetti A, Petrarulo F. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial. J Nephrol 2000; 13: 444-9.
21. Sezer S, Özdemir FN, Yakupoglu U, Arat Z, Turan M, Haberal M. Intravenous ascorbic acid administration for erythropoietin-hyporesponsives anemia in iron loaded hemodialysis patients. Artif Organs 2002; 26: 366-70.
22. Kalantar-Zadeh K, Hoffken B, Wunsch H, Fink H, Kleiner M, Luft FC. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 1995; 26: 292-5.
23. Deira J, Martín M, Sánchez S, Garrido J, Núñ ez J, Tabernero JM. Evaluation of intestinal iron absorption, by indirect methods, in patients on hemodialysis receiving oral iron and recombinant human erythropoietin. Am J Kidney Dis 2002; 39: 594-9.
24. Gunell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal patients. Am J Kidney Dis 1999; 33: 63-72.
25. Barton JC, McDonnell SM, Adams PC, Brisstot P, Powell LW, Edwards CQ. Management of hemochromatosis. Ann Intern Med 1998; 129: 932-9.
26. Meléndez O. Intravenous vitamin C for erythropoietin resistance. Semin Dial 2000; 13: 335-6.
27. Ajayi OA, Nnaji UR. Effect of ascorbic acid supplementation on haematological response and ascorbic acid status of young female adults. Ann Nutr Metab 1990; 34: 32-6.
28. Nienhuis AW. Vitamin C and iron. N Engl J Med 1981; 304: 170-1.
29. Herbert V, Shaw S, Jayatilleke E. Vitamin C-driven free radical generation from iron. J Nutr 1996; 126 (suppl 4): S1213-20.
30. Pru C, Eaton J, Kjellstrand C. Vitamin C intoxication and hyperoxalemia in chronic hemodialysis patients. Nephron 1985; 39: 112-6.
31. Kalantar-Zadeh K, Kopple JD, Deepak S, Block D, Block G. Food intake characteristics of hemodialysis patients as obtained by food frequent questionnaire. J Ren Nutr 2002; 12: 17-31.
32. Descombres E, Hanck AB, Fellay G. Water soluble vitamins in chronic hemodialysis patients and need for supplementation. Kidney Int 1993; 43: 1319-28.
33. Stivelman J, Schulman G, Fosburg M, Lazarus JM, Hakim RM. Kinetic and efficacy of deferoxamine in iron-overloaded hemodialysis patients. Kidney Int 1989; 36: 1125-32.